Studying these young Alzheimer’s patients led to breakthroughs. Trump cut the funding

(By Jon Hamilton for NPR)

Some of the most important studies of potential treatments for Alzheimer’s disease rely on a group of participants who know they may never fully reap the benefits.

“It’s not for us,” says June Ward, 64, who carries a rare gene mutation that virtually guarantees she will get Alzheimer’s in the next few years. “It’s for my sister’s children and their children, so that they won’t have the same ‘nothing’ to choose from.” Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.